Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis

Giovanni Monteleone, Flavio Caprioli

Research output: Contribution to journalArticle

Abstract

Tanabe AAI LLC, a joint venture between Tanabe Seiyaku Co Ltd and aaiPharma Inc, is developing TA-2711E, an enema formulation of Tanabe's mucosal protectant ecabet, for the potential treatment of ulcerative colitis. By July 2004, phase III trials for ulcerative colitis had been initiated in Japan and phase II studies were ongoing in Europe and the US; this remained the case in May 2006.

Original languageEnglish
Pages (from-to)423-428
Number of pages6
JournalCurrent Opinion in Investigational Drugs
Volume8
Issue number5
Publication statusPublished - May 2007

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis'. Together they form a unique fingerprint.

  • Cite this